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Abstract
Checkpoint with FHA and RING finger domains (CHFR) was first recognized as an early mitotic checkpoint protein
that delayed the cell cycle in response to microtubule-targeting drugs. It is an E3 ubiquitin ligase that ubiquitinates
target proteins to direct them to the proteasome for degradation or to alter their activity. To date, however, the
downstream target proteins critical to CHFR’s normal cellular functions largely remain unidentified with the excep-
tion of the key mitosis regulators, and oncogenes, PLK1 and Aurora A kinases. Rapidly growing evidence in mice,
primary human tumors, and mammalian cell culture models indicate that CHFR may also function as a potent
tumor suppressor. Interestingly, studies reported to date suggest that CHFR both controls a novel prophase check-
point early in mitosis and regulates chromosome segregation later in mitosis to maintain genomic stability. In ad-
dition, loss of CHFR sensitizes cancer cells to microtubule poisons, altering chemoresponsiveness to taxanes and
making it a potential biomarker for chemotherapeutic response. Importantly, CHFR may be one of the few proteins
that are required for regulating the cell cycle and maintaining genomic instability to inhibit tumorigenesis.
Translational Oncology (2008) 1, 57–64
Introduction
Cancer is the second leading cause of death in the United States
(http://www.cdc.gov/nchs/fastats/lcod.htm). Cancers are a molecu-
larly complex set of diseases, often making them difficult to treat
due to a great variation in sensitivity to radiation and chemotherapy
drugs. Therefore, researchers and clinicians must identify the molec-
ular and genetic characteristics of a tumor, or “biomarkers,” to deter-
mine the best course of treatment. In the past 8 years, Checkpoint
with FHA and RING finger domains (CHFR) has gained attention
as a mitotic checkpoint protein with tumor-suppressive function that
has the potential to be a novel biomarker for chemotherapeutic re-
sponse to microtubule-targeting drugs such as taxanes. Here, we dis-
cuss what is currently known about the structure and function of
CHFR, as well as the growing amount of evidence supporting its role
as a tumor-suppressor protein and biomarker for taxane treatment.
CHFR Protein Structure and Homologs
CHFR was initially identified through a screen to find novel mi-
totic checkpoint proteins that contained a forkhead-associated (FHA)
domain [1]. In addition to the N-terminal FHA domain, CHFR was
also found to have a central RING finger domain and a C-terminal
cysteine-rich region (Figure 1) [1]. The functional relevance of the
FHA domain in CHFR remains largely unknown. However, its de-
letion creates a dominant-negative form of the protein, suggesting
that it is critical to its normal cellular function, and this domain
was recently found to be responsible for the antiproliferative effects
of CHFR [1–3]. The RING finger domain and the cysteine-rich re-
gion are better characterized. The zinc-binding RING finger domain
has proven to be required for the early prophase checkpoint function
of CHFR. It confers CHFR’s E3 ubiquitin ligase activity to create
ubiquitin chains on target proteins either through the amino acid
residue lysine-48, thereby targeting proteins to the proteasome for
degradation, or through lysine-63 linkages that may alter target pro-
tein function [4,5]. In addition to ubiquitinating target proteins, the
RING finger domain was also found to be necessary for CHFR auto-
ubiquitination [6]. The cysteine-rich region was identified as the re-
gion responsible for the interaction between CHFR and one of its
target proteins, Aurora A [7]. Recently, a putative C2H2 zinc-finger
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motif, which was renamed a PAR-binding zinc-finger (PBZ) motif,
was identified in the C-terminal cysteine-rich region of CHFR. This
region was found to be poly(ADP-ribosyl)ated by PARP1. Although
mutating the PBZ domain did not inhibit CHFR’s ubiquitinating
activity, it did impair the dominant-negative function of the FHA-
domain deletion mutant. There was also inconclusive evidence that
the PBZ motif may be required for CHFR’s early mitotic checkpoint
function [8]. Of interest, the targeting of proteins to portions of
the mitotic apparatus is dependent on the recognition of poly(ADP-
ribose) (PAR) by PAR-binding motifs.
According to the domain architecture and organization, there are
evolutionarily conserved protein orthologs of CHFR even in yeast,
both Saccharomyces cerevisiae and Schizosaccharomyces pombe (Figure 1)
[1,9]. These minimally described orthologs, defective in mitotic arrest
1 and 2 (DMA1 and DMA2), were found to be important in regu-
lating the mitotic spindle checkpoint, mitotic spindle position, and
cytokinesis through the septation-initiation network [9–11]. As will
be described later, two studies have indicated that human and mouse
CHFR may have similar functions as the yeast orthologs.
Interestingly, a human paralog of CHFR was also described recently.
RING finger protein 8 (RNF8) shares the FHA and RING domains
architecture of CHFR, although it seems to have diverged a bit in
terms of cellular function (Figure 1). Initially, RNF8 was described
as a mitotic protein important for spindle formation, cytokinesis,
and mitotic exit, much like the yeast orthologs [12]. However, unlike
CHFR, it was also characterized recently as an important DNA dam-
age response protein to double-strand breaks. RNF8 interacts with
phosphorylated MDC1, an interaction that is dependent on RNF8’s
FHA domain, to mediate double-strand break-associated ubiquitina-
tions and facilitate the accumulation of 53BP1 and BRCA1 at the sites
of DNA double-strand breaks [13,14]. In addition, both groups noted
that RNF8 can ubiquitinate histones H2A and H2AX and that the
loss of RNF8 expression by RNAi abrogated double-strand break re-
tention of the ubiquitin-binding protein RAP80 and increased cellular
sensitivity to ionizing radiation [13,14]. There is a growing body of
evidence that suggests that CHFR, unlike RNF8, does not mediate
a classic cellular response to DNA damage on the basis of the results
from commonly used assays to assess DNA damage response. Whereas
the role of CHFR in the cellular response to ionizing radiation has
been inconclusive [15,16], it does not seem to have a role in the
DNA damage response induced by cisplatin (CDDP), UV radiation,
or the topoisomerase inhibitors etoposide (VP16) and topotecan
[6,17,18].
Since its initial publication, studies on CHFR have primarily fo-
cused on its expression in cancer cells and potential role in oncogensis,
but some progress has also been made in identifying its biochemical
function and target proteins. This review will address the discoveries
that have been published to date for CHFR, including its mitotic
checkpoint functions, reported protein targets for its ubiquitin ligase
activity, and evidence supporting its role as a tumor-suppressor protein
and as a biomarker for chemotherapeutic response to taxanes.
CHFR Functions
The Microtubule Stress Prophase Checkpoint
As mentioned in the previous paragraphs, CHFR does not seem
to participate in the DNA damage checkpoint or DNA repair path-
ways. On the contrary, CHFR regulates an early mitotic checkpoint,
during prophase, in response to the disruption of normal microtu-
bule formation or stabilization as assessed after treatment with mi-
crotubule poisons such as nocodazole, colcemid, and taxanes [1].
During mitotic stress, CHFR temporarily delays the cell cycle by ap-
proximately 3 hours, during which chromosome condensation and
nuclear envelope breakdown are inhibited and cyclin B1/CDC2 is re-
stricted to the cytoplasm where it is inactive [1,16,17]. CHFR also reg-
ulates the coordination of chromosome condensation and centrosome
separation during prophase [1]. Together, these results identified CHFR
as the first key member of a novel early mitotic checkpoint in prophase,
referred to here as the CHFR-mediated prophase checkpoint.
The ability of CHFR to delay chromosome condensation has been
confirmed both by visually identifying a lack of condensed chromo-
somes and by the absence of phosphorylation of histone H3 on resi-
dues Ser10 and Ser28 when CHFR is overexpressed in several cell
lines [1,16,17,19]. In addition, the CHFR-mediated prophase check-
point is typically monitored by calculating the mitotic index of cells
treated with microtubule poisons; CHFR-expressing cells will have
fewer mitotic cells, as evidenced by condensed chromosomes and
no nuclear envelope, compared to nonexpressing cells [1,17,19,20].
Elegant studies performed by Kang et al. [5] in Xenopus laevis egg
extracts have begun to elucidate how CHFR regulates entry into mi-
tosis. As previously mentioned, CHFR delayed the onset of mitosis
by retaining inactive cyclin B1/CDC2 in the cytoplasm in human
cells. In X. laevis extracts, the addition of full-length CHFR, but
not RING finger mutants, resulted in prolonged inhibitory phos-
phorylation of CDC2 on residue Tyr15. In addition, CHFR delayed
the phosphorylation of the CDC2-regulatory proteins WEE1 and
Figure 1. The domain architecture of CHFR is evolutionarily conserved. CHFR and its human homolog, RNF8, share the same domain
architecture as the yeast orthologs DMA proteins in both Schizosaccharomyces pombe (Sp) and Saccharomyces cerevisiae (Sc). All of
the proteins have an N-terminal FHA domain and a central or C-terminal RING domain that confers the proteins’ ubiquitin ligase activities.
CHFR is the only member of the family that has a C-terminal cysteine-rich region.
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CDC25C at the G2-to-M transition. However, the steady state level
of expression for these proteins, and for the CDC25C regulatory pro-
tein CHK1, remained unchanged in the presence of CHFR, indicat-
ing that they were not probable ubiquitination targets. Therefore, it
is likely that the prolonged inhibitory phosphorylation of CDC2 at
Tyr15 is due to the overactivation of WEE1 kinase, which phosphor-
ylates CDC2 at Tyr15, and the inhibition of CDC25C phosphatase,
which is normally responsible for activating cyclin B1/CDC2 by re-
moving the inhibitory phosphorylation on Tyr15 of CDC2. However,
as these experiments were performed in Xenopus extracts, they remain
to be confirmed in mammalian cells.
One of the proteins that can regulate both CDC25C and WEE1
through phosphorylation is the polo-like kinase 1 (PLK1). Kang
et al. [5] determined that CHFR could, in fact, ubiquitinate PLK1
in X. laevis extracts. In support of this model, the E3 ubiquitin ligase
activity of CHFR through its RING finger domain is required for
proper prophase checkpoint function, suggesting that CHFR must
ubiquitinate a target protein for the cell cycle delay to occur. How-
ever, although the pathway described previously is a likely explana-
tion for the series of events that occurs downstream of CHFR in
response to mitotic stress, these results have not been easily replicated
in mammalian cells. The ability of CHFR to ubiquitinate and/or reg-
ulate PLK1 has not been consistently reproduced, raising questions
as to the legitimacy of this pathway in mammalian cells as discussed
further in the next paragraphs.
Another potential pathway for the CHFR-regulated mitotic stress
checkpoint during prophase is through the p38 stress-activated kinases
in which CHFR acts upstream of p38 through an as-of-yet unknown
mechanism [21]. There is also recent evidence that Sirtuin 2 (SIRT2),
a tubulin and histone deacetylase, may also participate in the same mi-
crotubule stress–induced prophase checkpoint as CHFR does. Like
CHFR, it was found that SIRT2 overexpression results in a decreased
mitotic index and inhibits chromosome condensation in response to
nocodazole or paclitaxel treatment and that the NAD-dependent tu-
bulin deacetylase activity of SIRT2 was required for this response [22].
Finally, another potential player in the mitotic stress–induced prophase
checkpoint is sensitivity to nitrogen mustard 1 (SNM1). Akhter et al.
[23] found that mouse embryonic fibroblasts from Snm1 knockout
mice behaved like cells that had lost CHFR expression. Snm1-null cells
arrested during the spindle checkpoint with condensed chromosomes
and separated (and duplicated) centrosomes after nocodazole exposure,
whereas wild type cells from littermates arrested with decondensed
chromosomes and unseparated centrosomes. Furthermore, Snm1 wild
type cells delayed mitotic entry by approximately 4 hours and main-
tained cyclin A expression longer, indicating an arrest in prophase,
when compared to null fibroblasts [23]. Much like CHFR-null cells,
Snm1−/− mouse embryonic fibroblasts were less likely to survive noco-
dazole treatment when compared to wild type cells [23]. Of interest,
because the CHFR homolog RNF8 can regulate 53BP1, Akhter et al.
[23] also found that SNM1 could also interact with 53BP1 and the
APC/cyclosome complex in HeLa cells [12]. Together, these observa-
tions suggest that a currently unrecognized pathway of protein inter-
actions involving CHFR is critical for normal progression through the
recently described prophase checkpoint.
The Mitotic Spindle Assembly Checkpoint
In addition to participating in an early mitotic checkpoint during
prophase, a few reports indicate that CHFR may be required for
the regulation of later events in mitosis, such as chromosome seg-
regation to maintain genomic stability. Embryonic fibroblasts from
Chfr knockout mice showed not only a prolonged time in prophase
but also an extended amount of time in anaphase. The Chfr-null
mouse embryonic fibroblasts, which became aneuploid in culture, also
displayed lagging chromosomes during anaphase, failed nuclear seg-
regation, and multinucleated cells indicating failed cytokinesis [7].
In addition, immortalized human mammary epithelial cells that had
stably decreased CHFR expression by shRNA also became aneuploid
[19]. When MCF10A immortalized human mammary epithelial cells
were transiently transfected with siRNA targeting CHFR, they became
aneuploid within 72 hours [24]. A role for CHFR in regulating chro-
mosome segregation and the mitotic spindle assembly checkpoint was
further supported by the finding that the key mitotic spindle check-
point proteins BUBR1 and MAD2 were not properly localized to
the kinetochores during metaphase in MCF10A cells lacking CHFR
expression by RNAi [24]. This mislocalization was correlated with
impaired MAD2/CDC20 complex formation during nocodazole
treatment, which is required to prevent the anaphase-promoting
complex (APC/C) from prematurely signaling the onset of anaphase
before all of the sister chromatids are attached to the mitotic spindle
[24]. This apparent mitotic spindle checkpoint defect was further
supported by the characterization of an array of mitotic defects in-
cluding misaligned chromosomes at the metaphase plate, lagging
anaphase chromosomes, multipolar mitotic spindles, and tetraploid
binucleated giant cells in MCF10A cells lacking CHFR by siRNA
[24]. In support of these findings, recently published bioinformatics
evidence indicated that CHFR may contain a KEN box motif, sug-
gesting that CHFR may be targeted for proteasome-mediated degra-
dation by the APC/C-CDH1 complex, which is a critical component
of the mitotic spindle assembly checkpoint and the regulatory com-
plex that controls mitotic exit [25]. Therefore, CHFR has multiple
mitotic checkpoint functions and, contrary to initial thought, does
not function only in response to mitotic stress due to microtubule-
targeting drugs.
Regulation of Cellular Proliferation
Multiple cell culture models have indicated that CHFR can function
as a negative regulator of proliferation. Decreasing CHFR expression by
RNAi in MCF10A and HPV4-12 immortalized mammary epithelial
cells caused a decrease in population growth rates, whereas overexpress-
ing CHFR in the Hs578T breast cancer cell line decreased population
growth rates. This was further supported by the finding that there was
an increased frequency of phosphorylation of histone H3 on Ser28 in
CHFR knockdown cells and a decreased frequency of histone H3
phosphorylation in CHFR overexpressing cells. This indicated that cells
with altered CHFR expression entered into, or progressed through,
mitosis at different rates compared to parental cells [19]. In addition,
Fukuda et al. [3] discovered that overexpressing CHFR also inhibited
cellular proliferation in HCT116 and RKO colon cancer cells, and this
antiproliferative function was dependent on the FHA domain of
CHFR. However, the mechanism(s) by which CHFR negatively regu-
lates cellular proliferation remains to be elucidated.
CHFR Interacting Proteins
Polo-Like Kinase 1
As mentioned previously, there is evidence that CHFR can ubiqui-
tinate PLK1 in Xenopus extracts, but tests to assess the ability of
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CHFR to regulate PLK1 activity or protein levels in mammalian cells
have been inconclusive. Findings in support of CHFR controlling
PLK1 include results indicating that overexpressed CHFR mutants,
which mimic unphosphorylated CHFR, can decrease PLK1 expres-
sion and kinase activity in HeLa cells [15]. Of interest, mouse embry-
onic fibroblasts from Chfr knockout mice were found to overexpress
PLK1 compared to cells from wild type and heterozygous littermates,
suggesting that CHFR can ubiquitinate PLK1 to target it for degra-
dation [7].
To the contrary, there are other reports that have not been able to
find a correlation between CHFR expression and PLK1 expression or
activity. For example, Matsusaka and Pines [21] were unable to find
an association between PLK1 expression and induction of the
CHFR-regulated prophase checkpoint due to colcemid treatment.
In addition, other studies have not been able to find a relationship
between CHFR expression and the amount of PLK1 protein, either
as a trend among breast cell lines or after CHFR overexpression in
HCT116 cells [16,20]. It is apparent that more work is required to
determine whether PLK1 is a target for CHFR-mediated ubiquitina-
tion and regulation. Perhaps the interaction is specific for a particular
species, tissue, or treatment.
Aurora A Kinase
A key protein that regulates the activity and translocation of cyclin
B1 to the nucleus to initiate mitosis is Aurora A kinase [26]. There-
fore, Aurora A has also been speculated to be a target for ubiquitina-
tion by CHFR. Summers et al. [16] analyzed Aurora A expression
and activation in HCT116 cells overexpressing CHFR and found
that, although there was no change in Aurora A expression or local-
ization to the centrosomes, they did discover that the nocodazole-
induced CHFR-mediated mitotic delay was associated with the inactive
Aurora A that was unphosphorylated at residue Thr288 at the cen-
trosomes. Compelling evidence that CHFR ubiquitinates Aurora A
was provided by Yu et al. [7] in which they found that Aurora A was
overexpressed in Chfr-null mouse embryonic fibroblasts and tissues.
In addition, using human cell lines, they determined that the C-
terminal cysteine-rich region of CHFR interacts with the N-terminus
of Aurora A by immunoprecipitation and that this interaction led to
the ubiquitination of Aurora A [7]. In support of these findings, we
have also reported that decreasing CHFR expression by siRNA in
MCF10A-immortalized human mammary epithelial cells led to Au-
rora A overexpression, although its localization to the centrosomes
was not perturbed, and that overexpressed Aurora A could interact
with endogenous CHFR by immunoprecipitation [24].
Proteins Regulating Ubiquitination Activity
Because CHFR has been described as an E3 ubiquitin ligase due to
the presence of its RING domain, there must be E2 enzymes that it
interacts with for it to function. CHFR has been shown to use the E2
ubiquitin-conjugating (Ubc) proteins UBC4, UBC5A, and UBC5B
to form Lys48-based polyubiquitin chains, but not E2 enzymes
UBCH7, UBCH8, or UBCH10 [4,5]. CHFR has also been found
to be able to interact with the E2 enzyme complex UBC13-MMS2
heterodimer to form lysine-63–linked polyubiquitin chains, which are
associated with modifying protein function, not targeting them for deg-
radation by the proteasome [4]. In addition to ubiquitin-conjugating
E2 enzymes, CHFR has been shown to interact with the deubiqui-
tinating protein ubiquitin-specific protease 7 (USP7) by immunopre-
cipitation [27]. USP7 was found to deubiquitinate CHFR and
inhibit its auto-ubiquitinating activity, thereby preventing the degra-
dation of CHFR [27]. Interestingly, USP7 and CHFR both localize
to PML bodies in the nucleus; in particular, CHFR has been shown
to be in PML bodies in interphase cells [2,27].
Additional Interacting Proteins
Due to the role of CHFR in initiating a cell cycle delay in response
to microtubule poisons, it is feasible that it may interact with tubulin
proteins. Recently, Privette et al. found that CHFR could interact with
α-tubulin, by both immunoprecipitation and GST pull down experi-
ments [24]. Importantly, CHFR was found to ubiquitinate α-tubulin
when MCF10A cells were treated with nocodozaole to induce the
checkpoint [24]. In the same work, CHFR and MAD2 were shown
to interact by yeast two-hybrid analysis, coimmunoprecipitation,
and colocalization, which further supported the hypothesis that
CHFR may function in the mitotic spindle assembly checkpoint in
addition to the prophase checkpoint [24]. Finally, it was determined
that protein kinase B (PKB) could phosphorylate CHFR on residues
Thr39 and Ser208, potentially inhibiting the ubiquitin ligase activity
of CHFR; however, phosphorylation-defective mutants of CHFR did
not alter the checkpoint response to paclitaxel [15]. Bothos et al. [4]
also found that CHFR was phosphorylated during mitosis, although
they did not determine which kinase was responsible.
CHFR and Cancer
Mutations, Alternative Transcripts, and
Chromosomal Aberrations
CHFR has been implicated as a tumor suppressor in multiple can-
cers despite the fact that no heritable mutations in germline cells as-
sociated with a predisposition to cancer phenotypes have been
identified and few mutations in somatic cancer cells have been de-
scribed. Although many groups have not been able to identify coding
mutations in the CHFR gene, particularly in breast and colon can-
cers, several single-nucleotide polymorphisms (SNPs) have been iden-
tified [20,28,29]. However, three missense mutations in CHFR were
found in primary non–small cell lung cancers, that is, two mutations
between the FHA and RING domains and one in the cysteine-rich
region, all three of which were unable to rescue the CHFR checkpoint
in DLD-1 cells during nocodazole treatment [29]. However, even
these mutations were rare events, because they were only found in
three patients, all of who were smokers, of 53 different patient samples
tested [29]. Recent published data have indicated that one of these
coding SNPs, V539M (Accession No. NM_018223; V580M for Ac-
cession No. AF_170724) found within the C-terminal cysteine-rich
region, was significantly associated with a lower risk of colorectoral
cancer if the patient had the methionine amino acid instead of the
valine [30]. This SNP was also strongly associated with the absence
of metastases, TNM stage, and microsatellite instability, all of which
indicate a favorable prognosis. This variant was within the hap 10
(TGACTA) haplotype block that also contained the P138L SNP,
which had correlated with the microsatellite instability phenotype
[30]. Two additional deletion mutations have also been identified
in which either residues 135 to 146 were deleted between the FHA
and RING domains or residue Ala470 was deleted in the C-terminal
cysteine-rich region [29].
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Although they have not been studied extensively, alternative
mRNA transcripts have been identified for CHFR. Toyota et al.
[31] identified transcripts that were missing exons 2, 5, and/or 6
and the transcript missing exon 2 is believed to result in an isoform
lacking the FHA domain [1]. This isoform was also found to be
highly expressed in cancer cells when compared with matched nor-
mal tissues [31]. Although full-length CHFR was found to suppress
cell growth when overexpressed, the FHA domain deletion mutant of
CHFR was less effective in suppressing cell growth and had been pre-
viously identified as a dominant negative form of CHFR [1,31].
CHFR is located on human chromosome 12q24.33, which has
been characterized as a site of allelic imbalance in many cancers. De-
letion of 12q24 has been described in adenoid cystic carcinoma and
as a prognostic indicator of cancer recurrence in Wilms tumor and
pituitary adenomas [32–34]. Chromosome loci 12q24 has also been
associated with the presence of a metastasis suppressor gene, because
gain of 12q24 correlated with metastasis-free survival in breast cancer
patients and decreased metastatic potential of prostate cancer cells
[35–37]. Further characterization of 12q24 would be required to de-
termine whether CHFR is the gene responsible for predicting cancer
recurrence and metastasis in these association studies.
CHFR Expression and Correlations with
Clinicopathologic Variables
Many studies have focused on studying the loss of CHFR mRNA
expression due to promoter hypermethylation in cancers compared
to normal cells and tissues, and they are summarized in Table 1
[17,18,20,28,31,38–62]. Although CHFR mRNA expression has
been shown to be decreased or lost in many cancers, sometimes up
to 50% of samples, promoter hypermethylation only accounts for a
percentage of these instances and is often tissue-dependent [20]. In
particular, 16% to 53% of cancers of the gastrointestinal tract have
hypermethylated promoters of the CHFR gene; however, this is ex-
tremely rare in gynecologic cancers with the exception of HPV-
positive cervical carcinomas [31,45,57,58,61]. As an example, 50%
of breast cancer cell lines have decreased or lost CHFR expression com-
pared to immortalized human mammary epithelial cells, but only 8%
of the cell lines had a methylated promoter [20].
Altered mRNA expression of CHFR has been correlated with clinical
and pathologic variables. In particular, low or lost CHFR was associated
with a high mitotic index in colorectal and breast cancers [20,31]. A
hypermethylated CHFR promoter was also associated with advanced
patient age, high tumor grade, advanced stage, poor differentiation, fe-
male gender, and taxane sensitivity [38,40,45,46,51,54,56,61]. Of
these correlations, high mitotic index, advanced tumor stage, and tax-
ane sensitivity have been replicated among different research groups
[20,31,38,40,51,56].
Only a few studies recently have reported on the frequency of al-
tered CHFR protein expression in cancers versus normal tissue. In
breast cancers, 41% of cultured cell lines were found to have decreased
or lost CHFR expression by Western blot analysis, whereas 36% of
primary invasive breast cancers were negative for CHFR expression
by immunohistochemistry [19]. Of interest, the loss of CHFR expres-
sion in primary invasive breast cancers strongly correlated with
larger tumor size and there was a trend of association between
CHFR-negative and estrogen receptor (ER)-negative status [19].
Milne et al. [63] found that 33% of gastric cancers were negative
for CHFR expression by immunohistochemistry, which correlated
with a diffuse histologic diagnosis. Importantly, using immunohisto-
chemistry, CHFR localization to the nucleus was altered in 66% of
malignant peripheral nerve sheath tumors. In the same samples, de-
creased CHFR expression was associated with a multitude of clinical
and pathologic variables including young age, site of tumor to the
trunk, head, or neck, presentation in recurrent tumors, increased mi-
totic index, increased Ki67 staining for proliferation, abnormal karyo-
type, and poor patient prognosis [64].
CHFR Is a Tumor Suppressor and Regulator of
Genomic Stability
The first indication that CHFR was a potent tumor suppressor
was the creation of the Chfr knockout mouse, which was viable with
no developmental defects [7]. A small percentage (9%) of these mice
developed lymphomas by 40 weeks of age, and later, they were prone
to developing spontaneous cancers of epithelial origin, primarily
lung, liver, and gastrointestinal tumors. Fifty percent of the knockout
mice also developed skin tumors after treatment with the chemical
carcinogen dimethylbenz(a)anthracene at 4 months of age compared
with none of their wild type littermates [7]. There was also an indica-
tion that the loss of CHFR led to cellular transformation because em-
bryonic fibroblasts from the mice were able to form colonies in culture
[7]. Interestingly, CHFR was found to be important for maintaining
genomic stability in the embryonic fibroblasts from the Chfr-null
mice. About 30% of the cells became aneuploid after four passages
likely due to several mitotic defects that were observed, including lag-
ging anaphase chromosomes, failed nuclear segregation, and failed cy-
tokinesis, which resulted in 17% of the cells becoming multinucleated
[7]. Of interest, they discovered that down-regulating Aurora A by
RNAi rescued the genomic instability phenotype in Chfr-null mouse
embryonic fibroblasts [7].
A multitude of cell culture assays using immortalized human
mammary epithelial cell lines and the Hs578T breast cancer cell line
provided further evidence that CHFR was a tumor suppressor in
human cells. Two immortalized human mammary epithelial cell
lines (HPV4-12 and MCF10A) that had decreased CHFR expression
by RNAi developed many phenotypes reminiscent of malignant
progression including increased population growth rates, higher mi-
totic index, enhanced invasion and motility, increased sensitivity to
microtubule-targeting drugs, aneuploidy, and colony formation in
soft agar [19]. MCF10A cells that had decreased CHFR expression
by RNAi also displayed an epithelial-to-mesenchymal transition in
morphology and an increase in the number of nucleoli. Interestingly,
many of these tumorigenic phenotypes—particularly the growth
rates, mitotic index, sensitivity to microtubule poisons, cellular inva-
sion through Matrigel, and cellular motility—were reversed in a
breast cancer cell line, Hs578T, which was transduced with a retro-
virus to overexpress CHFR [19]. Further work found that siRNA
against CHFR in MCF10A caused the cells to become aneuploid
within 72 hours of transfection because of four mitotic defects: 1)
misaligned chromosomes at the metaphase plate; 2) lagging anaphase
chromosomes; 3) multipolar, poorly formed mitotic spindles indi-
cating centrosome amplification; and 4) binucleated giant cells indi-
cating cytokinesis defects [24]. The complementary data from the
knockout mouse and human cell culture have provided strong evi-
dence that CHFR, in addition to its checkpoint function, was in-
volved in regulating growth rates, cellular invasion and motility,
and genomic stability, which indicated that CHFR could be a potent
tumor suppressor.
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CHFR as a Potential Biomarker for Chemotherapeutic
Response to Taxanes
As indicated in the previous paragraphs and in Table 1, CHFR pro-
moter hypermethylation correlated with taxane sensitivity in gastric
cancers and cervical carcinoma [38,51]. In support of these findings,
cultured cells that were transfected to overexpress CHFR showed a de-
crease in apoptotic response to taxanes and enhanced cell survival,
whereas decreasing CHFR by RNAi resulted in enhanced sensitivity
(i.e., increased apoptotic response) to taxanes [1,17–19]. These reports
have indicated that the CHFR expression status of cancers might be an
excellent biomarker for tumor response to taxane treatment. However,
this poses a very interesting dichotomy for CHFR expression. On one
hand, losing the tumor-suppressive function of CHFR may lead to a
larger, more advanced and aggressive tumor, conversely, an absence of
CHFR expression might actually be favorable because it would be a
positive indicator of chemotherapeutic response to taxane treatment.
Future work studying the potential role of CHFR as a biomarker
for chemotherapeutic response to taxanes in diverse tissues, and the
mechanism of this response, would definitely be valuable both at
the bench and at the clinic.
Conclusions
Since CHFR was first described in 2000, several investigators have
been further characterizing its expression patterns in normal and ma-
Table 1. The Frequency of CHFR Promoter Hypermethylation and Correlations with Clinicopathological Variables.
Cancer Tissue Percent Hypermethylated Correlations and Findings Reference
Lung cancer 19% (7/37) of primary cancers Infrequent SNPs in coding region [53]*
19% (3/16) of cell lines
Esophageal cancer 16.3% (7/43) of primary cancers None found [57]*
26.7% (4/15) of cell lines
Colon adenocarcinomas 37% (11/30) of primary cancers Some methylation in normal colon [42]*
Non–small cell lung 10% (2/20) of primary cancers
Colorectal cancer 40% (25/63) of primary cancers Associated with increased mitotic index [31]*
Colorectal adenomas 53% (27/51) of primary cancers
Head and neck cancer 30% (16/54) of primary cancers
Hepatocellular cancer 0% (0/20) of primary cancers
Colon cancer 36% (8/22) of primary cancers None tested [28]*
Colon cancer 43% (9/21) of cell lines
Breast cancer 0% (0/19) of cell lines
Breast cancer 8% (2/24) of cell lines Low expression associated with high mitotic index [20]†
Gastric cancer 39% (24/61) of primary cancers None tested [18]‡,§
Gastric cancer 20% (4/20) of cell lines
Gastric cancer 35% (25/71) of primary cancers None found [47]*
Gastric cancer 20% (2/10 cell lines)
Gastric cancer 44% (19/43) of primary cancers None tested [49]*,§
Gastric cancer 67% (8/12) of cell lines
Biliary tract carcinomas 16% (6/37) of primary cancers None found [59]*
Low-grade noninvasive gastric neoplasia 10% (1/10) of primary cancers Methylation correlated with advanced patient age and high tumor grade [46]*
High-grade noninvasive gastric carcinoma 45% (10/22) of primary cancers
Submucosal invasive gastric adenocarcinomas 35% (7/20) of primary cancers
Colorectal cancer 31% (19/62) of primary cancers Associated with MLH1 promoter hypermethylation, microsatellite instability [39]*
Cutaneous T-cell lymphoma 19% (5/28) of primary cancers None tested [60]§,¶
Nasopharyngeal carcinomas 61% (22/36) of primary cancers None found [41]*,§
88% (7/8) of cell lines
Oral squamous cell carcinoma 31% (4/13) of primary cancers Low expression associated with high mitotic index and taxane sensitivity [17]‡
22% (2/9) of cell lines
Acute myelocytic and lymphocytic leukemia 39% (16/41) of primary cancers None tested [44]*
Hepatocellular cancer 35% (22/62) of primary cancers Correlated with infiltrative growth pattern and advanced stage [56]
Gastric cancer 37% (15/41) of primary cancers No correlation with response to Taxol treatment [62]‡
Breast cancer 0.9% (1/110) of primary cancers None tested [58]*
Gastric cancer 52% (24/46) of primary cancers Correlated with clinical response to Taxol treatment [51]*
Esophageal cancer 24% (9/38) of primary cancers Correlated with female gender, but not with tumor stage [55]*
Gastric cancer 30% (16/53) of primary cancers
Colorectal cancer 26% (25/98) of primary cancers None tested [54]
Endometrial cancer 12% (6/50) of primary cancers Correlated with poorly differentiated adenocarcinomas [61]*
Ovarian cancer 0% (0/48) of primary cancers None tested [52]*
Cervical adenocarcinomas 12% (2/14) of primary cancers Correlated with taxane sensitivity [38]*
Cervical carcinoma 33% (2/6) of cell lines
HPV+ cervical squamous cell carcinoma 31% (5/16) of primary cancers Methylation designated as a late event [45]#
HPV+ cervical adenocarcinoma 50% (4/8) of primary cancers
HPV+ cervical carcinoma 56% (5/9) of cell lines
Head and neck squamous cell carcinoma 25% (7/28) of primary cancers Correlated with stage IV cancer [40]#
Colorectal cancer 41% (29/71) of primary cancers hMLH1 promoter methylation, gain of chromosome 8q, BRAF mutations [43]*
Gastric cancer 48% (12/25) of primary cancers None tested [48]**
Colorectal cancer 24% (217/888) of primary cancers None tested [50]**
*Methylation-specific polymerase chain reaction.
†Treatment with 5-aza-dC.
‡Combined bisulfite restriction analysis.
§Bisulfite sequencing.
¶CpG island microarray.
#Methylation-specific multi-plex ligation-dependent probe amplification.
**MethyLight quantitative polymerase chain reaction.
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lignant cells and trying to elucidate its functional roles in cell biology.
At present, we are just beginning to understand how the CHFR-
regulated prophase checkpoint might work in response to microtu-
bule disruption. CHFR can regulate mitotic entry, particularly in
the presence of microtubule poisons such as taxanes, by controlling
cyclin B1/CDC2 activity and translocation to the nucleus. The
mechanisms behind this regulation are unclear, although it likely
involves CHFR-mediated ubiquitination and regulation of PLK1
and/or Aurora A kinases. More recently, CHFR has been implicated
as a regulator of genomic stability. Cells that have lost or decreased
expression quickly became aneuploid, a hallmark of many cancers,
due to an impaired mitotic spindle checkpoint, which would result
in chromosome mis-segregation. Interestingly, CHFR seems to have
multiple checkpoint functions, because it participates in cellular re-
sponse to microtubule poisons early in mitosis during prophase and
it is also important for chromosome segregation, mitotic spindle for-
mation, and the function of the mitotic spindle assembly checkpoint.
In addition, there is a rapidly growing amount of evidence to sup-
port the hypothesis that CHFR is also a potent tumor suppressor.
CHFR has been shown to be a tumor suppressor in mice, which is
further supported by studies in human cancer cells. Its expression often
is lost or decreased in cancers when compared to normal tissues,
sometimes due to promoter hypermethylation that varies by tissue.
The pathways that regulate the transcriptional expression of CHFR
are unknown, although the identification of these pathways will likely
explain how/why expression is lost in cancers when promoter hyper-
methylation is not the cause. Surprisingly, CHFR expression alters cel-
lular motility and invasion in cell culture models, which is supported
by the presence of an unidentified “metastasis suppressor” at the chro-
mosomal location where CHFR is found. This novel, poorly charac-
terized role for CHFR certainly deserves more attention. Finally,
CHFR is emerging as an important cancer biomarker for chemother-
apeutic response to taxane treatment, although future research is re-
quired to verify this finding before translating these preliminary
results for use in the clinic.
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